. 2021 May;7(3):503-505.

doi: 10.1016/j.euf.2021.03.027. Epub 2021 Apr 23.

Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging

Teresa Marsden¹, Neil McCartan², Joanna Hadley², Steve Tuck³, Louise Brown⁴, Anna J Haire⁵, Charlotte L Moss⁵, Saran Green⁵, Mieke Van Hemelrijck⁵, Ton Coolen⁶, Aida Santaolalla⁷, Elizabeth Isaac⁸, Giorgio Brembilla⁸, Douglas Kopcke⁹, Francesco Giganti¹⁰, Harbir Sidhu⁸, Shonit Punwani⁸, Mark Emberton², Caroline M Moore²; ReIMAGINE Study Group

Affiliations

¹ UCL Division of Surgical & Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: teresa.marsden@ucl.ac.uk.
² UCL Division of Surgical & Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
³ ReIMAGINE Consortium Patient Representative.
⁴ MRC Clinical Trials Unit, University College London, London, UK.
⁵ Translational Oncology & Urology Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
⁶ London Institute for Mathematical Sciences, London, UK.
⁷ Cancer Epidemiology Group, Division of Cancer Studies, King's College London School of Medicine, London, UK.
⁸ Centre for Medical Imaging, University College London, London, UK.
⁹ Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁰ UCL Division of Surgical & Interventional Sciences, University College London, London, UK; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 33896710
PMCID: PMC7614671
DOI: 10.1016/j.euf.2021.03.027

Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging

Teresa Marsden et al. Eur Urol Focus. 2021 May.

. 2021 May;7(3):503-505.

doi: 10.1016/j.euf.2021.03.027. Epub 2021 Apr 23.

Authors

Affiliations

¹ UCL Division of Surgical & Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: teresa.marsden@ucl.ac.uk.
² UCL Division of Surgical & Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
³ ReIMAGINE Consortium Patient Representative.
⁴ MRC Clinical Trials Unit, University College London, London, UK.
⁵ Translational Oncology & Urology Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
⁶ London Institute for Mathematical Sciences, London, UK.
⁷ Cancer Epidemiology Group, Division of Cancer Studies, King's College London School of Medicine, London, UK.
⁸ Centre for Medical Imaging, University College London, London, UK.
⁹ Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁰ UCL Division of Surgical & Interventional Sciences, University College London, London, UK; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.

PMID: 33896710
PMCID: PMC7614671
DOI: 10.1016/j.euf.2021.03.027

Abstract

ReIMAGINE Screening is a single-centre study assessing the feasibility of biparametric magnetic resonance imaging as a screening tool for prostate cancer. The study outcomes will take us a step towards more accurate and less harmful prostate cancer screening.

Trial registration: ClinicalTrials.gov NCT04063566.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Caroline M. Moore receives funding from Prostate Cancer UK, Movember, the Medical Research Council, Cancer Research UK, and the National Institute of Health Research (NIHR); receives fees for HIFU proctoring from SonaCare; has received speaker fees from Astellas and Janssen; and receives research support for photodyanamic therapy from Spectracure. Mark Emberton serves as a consultant/educator/trainer for Sonacare, Exact Imaging, Angiodynamics, and Profound Medical; and receives research support from the NIHR UCLH/UCL Bio-medical Research Centre. Shonit Punwani receives research support from the NIHR UCLH/UCL Biomedical Research Centre. Francesco Giganti is funded by a UCL Graduate Research Scholarship and a Brahm PhD scholarship in memory of Chris Adams. Ton Coolen receives funding from Cancer Research UK and is director of Saddle Point Science. The remaining authors have nothing to disclose.

Figures

**Fig. 1**
ReIMAGINE Prostate Cancer Screening: Study Design. ReIMAGINE Screening is recruiting eligible men from partner general practitioner (GP) surgeries. Each participant will receive a prostate specific antigen (PSA) blood test and a research MRI of the prostate consisting of biparametric clinical sequences (axial T2-weighted and diffusion-weighted acquisitions) and research-specific sequences. Clinical sequences will be used to determine screen status within the study. A screen-positive result is defined as a suspicious lesion on biparametric MRI or PSA density of ≥0.12 ng/mL/cm³ using MRI-derived prostate volume. All screen-positive participants will be invited to undergo standard-of-care prostate cancer investigations. MRI = magnetic resonance imaging; NHS = National Health Service; eCRF = electronic case report form.

See this image and copyright information in PMC

References

1. Cancer Research UK. Prostate cancer statistics. www.cancerresearchuk.org/health-professional/cancer-statistics/statistic... .
1. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350:2239–46. - PubMed
1. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–78. - PubMed
1. Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319:883–95. - PMC - PubMed
1. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123:592–9. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging

Affiliations

Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical